NPPA Fixes Prices Of 58 Drug Formulations
The national drug pricing regulator NPPA has fixed the retail and ceiling prices of 58 formulations used for treatment of various ailments, including cardiac conditions, anxiety disorders, Hepatitis C and diabetes.
While the National Pharmaceutical Pricing Authority has fixed the retail prices of 56 formulations, it has also capped the ceiling prices of two formulations, a notification on the regulator's website said.
The prices have been fixed or revised under the Drug (Prices Control) Order, 2013, it added.
The regulator has fixed the retail prices of drugs manufactured and marketed by various firms. The drugs include Sofosbuvir and Ledipasvir tablets used for treatment of hepatitis C.
It has also fixed the retail price of Teneligliptin Metformin tablet (Teneblu M Forte) used for treatment of diabetes.
The NPPA has capped the ceiling prices of Digoxin and Furosemide oral liquids.
The regulator is mandated to fix or revise the prices of controlled bulk drugs and formulations and to enforce prices and availability of the medicines in the country.
It also monitors the prices of decontrolled drugs in order to keep them at reasonable levels.
It is also entrusted with the task of recovering amounts overcharged by manufacturers for the controlled drugs from the consumers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
